anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Blomia tropicalis (B. tropicalis) has been reported to impose an increased risk of allergic diseases. However, few characteristics of the unknown allergen components responsible for B. tropicalis allergy and clinical relevance have been fully identified.
METHODS: We synthesized and characterized the physicochemical properties and cross-reactivity of the newly discovered recombinant B. tropicalis group 41 allergen (rBlo t 41). Subsequently, sera were collected from 107 B. tropicalis allergic subjects to evaluate the prevalence of the rBlo t 41. Lastly, its allergenicity was tested in humans by basophil activation assays, and in mice by a model of allergic asthma.
RESULTS: The mature protein of rBlo t 41 was described as 104 amino acids long and 15.8 kDa, and its limited cross-reactivity was observed between allergens of house dust mites (HDM). Sensitization rate of rBlo t 41 (56.07 %) was lower than rBlo t 2 (76.29 %) and rBlo t 5 (69.07 %) in our study. Besides, rBlo t 41 elicited CD63 upregulation in basophils, whereas rBlo t 41-sensitized mice generated rBlo t 41-IgE and developed allergic airway inflammation after allergen exposure. Of note, component-based tests showed a high area under curve value (AUC = 0.75) of rBlo t 41, displaying its favorable diagnostic potential in B. tropicalis allergy.
CONCLUSIONS: rBlo t 41 was identified as a candidate novel major allergen with good diagnostic potential in B. tropicalis sensitization. Additionally, we provided strong evidence about rBlo t 41 on the clinically relevant manifestations in B. tropicalis allergies, conducive to facilitating the development of component-resolved diagnosis.
Control Group will comprise 100 women in labor either stimulated or induced by oxytocin requesting epidural analgesia (ELA). The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA.
Children with developmental delays benefit from early intervention. Therefore, it is very important to detect developmental delays as early as possible. In recent years, there has been increasing interest in designing and providing early intervention programs to improve developmental outcomes for infants at risk for developmental delay for neurodevelopmental disorders. Early intervention includes services provided to children from birth to age five to promote the child's health and well-being, develop emerging skills, minimize developmental delays, correct existing or emerging disabilities, prevent functional impairment, and promote parental compliance. When the literature is examined, it is seen that early intervention approaches are mostly implemented in preterm babies and focus on motor skills. An example of studies carried out with this attitude is Neurodevelopmental Treatment (NGT), which is frequently used in early intervention approaches in Turkey. Another early intervention approach that includes intensive motor training is Goal, Activity and Motor Enrichment (GAME). GAME early intervention approach is also used in extremely preterm babies with a high risk of developmental delay; It has been used in studies as an intervention approach that includes goal-oriented motor training, environmental enrichment and family education. Another early intervention approach that addresses parent education and environmental enrichment principles is the Supporting Play, Exploration and Early Development Intervention (SPEEDI). The SPEEDI program was applied to preterm babies in a similar way to the GAME program. Other approaches used by occupational therapists for children at risk of developmental delay in the literature are home-based and routine-based approaches.

When the literature is examined, it is seen that early intervention programs are mostly carried out with premature babies and/or for the diagnosis of cerebral palsy (CP). Early intervention approaches in the literature include intensive motor training, parent training, environmental enrichment, participation support and home visits. Although it is stated in the literature that development should be considered as a whole and sensory, cognitive and motor outcomes are interrelated, it is seen that interventions for sensory and cognitive skills are not included in early intervention studies. Therefore, the aim of our study is to improve the sensory, cognitive and motor skills of the early occupational therapy intervention program, which includes sensory, cognitive and motor strategies based on the principles of Goal, Activity and Motor Enrichment-GAME, which is an evidence-based early intervention program, in babies at risk of developmental delay of 24-36 months. to examine its effect.
Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
This invention relates to a method to efficiently extract diosgenin from the root and stem of dioscorea zingiberensis without fermentation, that is, a proper amount of water is added and the root and stem of dioscorea zingiberensis are pulverized. Fiber sediments and starch in the sludge are separated by a mechanical method and the pH value of the sludge is immediately adjusted to below 4.5 with acid. The adjusted and unfermented sludge is concentrated and acid hydrolyzed with the aid of hydrolysis agent. The hydrolyzed mixture is filtered to remove acid, neutralized, dried, extracted with organic solvent and crystallized so as to obtain diosgenin product.as fermentation is purposely inhibited and avoided during acid hydrolysis of the concentrated sludge in this invention, not only the stench problem is solved, but also the hydrolysis effect is greatly promoted. The extracted diosgenin product is of good crystallinity, high purity, white color and its melting point can be above 200 deg. C.
The invention comprises hydrazinium salts of the formula <FORM:0880334/IV (b)/1> (wherein R is a hydrogen or halogen atom, R1 and R11 are alkyl radicals each containing less than 8 carbon atoms or together with the nitrogen atom to which they are attached form a morpholino, piperidino, piperazino or 4-alkyl-piperazino radical, the 4-alkyl radical containing less than 8 carbon atoms, A is an alkylene radical of 2 to 4 carbon atoms and X is an anion bearing the charge n).  They may be prepared by reacting chloramine or hydroxylamine-O-sulphonic acid with the appropriate tertiary amine or by reaction of the hydrazine R1R11NNH2 with the appropriate N-(A-X)-substituted phenothiazine.  Anions may be exchanged by metathesis.  Examples are given and an extensive list of suitable anions derived from organic and inorganic acids is provided. Specification 858,488 and U.S.A. Specification 2,678,258, 2,710,248 are referred to.ALSO:Pharmaceutical compositions having sedative and anti-emetic properties comprise a hydrazinium salt of the formula <FORM:0880334/VI/1> (wherein R is a hydrogen or halogen atom, R1 and R1 are alkyl radicals each containing less than 8 carbon atoms or together with the nitrogen atom to which they are attached form a morpholino, piperidino, piperazino or 4-alkyl-piperazino radical, the 4-alkyl radical containing less than 8 carbon atoms, A is an alkylene radical of 2 to 4 carbon atoms and X is an organic or inorganic anion bearing the charge n) and a carrier therefor. Specification 858,488 and U.S.A. Specifications 2,678,258, 2,710,248 are referred to.
Participants assigned to the waitlist control will receive home visitation care as usual. At 6-months postpartum they will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client in practicing using the carrier and will provide materials to support continued learning.
Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
BACKGROUND: Text neck syndrome is an overuse condition that has become a global problem for all ages who use smartphones. Although therapeutic approaches are used to manage text neck syndrome, relatively little evidence exists on efficacy. This study aimed to investigate the effects of proprioceptive neuromuscular facilitation (PNF) techniques on individuals with text neck syndrome.
METHODS: Thirty-eight participants with text neck syndrome were randomly allocated to either the experimental or control group. Both groups performed the program including cervical range of motion, strengthening, and posture correction exercises for 6 weeks, 3 days a week, once a day for 10 repetitions. In the experimental group were included in a PNF program 3 days a week for 6 weeks. In the program, contract-relax and replication techniques were used. Pain intensity, cervical range of motion, cervical muscles' endurance, posture, and disability were assessed. Outcome measures were assessed at baseline and after 6 weeks.
RESULTS: Pain intensity, neck muscle endurance tests, posture, and disability scores significantly improved in both groups (P < .05). The cervical range of motion values in all directions were significantly increased only in the experimental group (P < .05). The improvements in pain intensity, neck muscle endurance tests, posture, and disability scores were greater in the experimental group compared with the control group (P < .05).
CONCLUSION: PNF could be used effectively to reduce neck pain and disability level and enhance cervical range of motion, cervical muscles' endurance, and posture in individuals with text neck syndrome.
FIELD: medicine, surgery. SUBSTANCE: one should carry out surgical treatment of the focus consisting of three-dimensional connecting incisions as Roman digit I, the direction of which coincides with that of gravitational force. Xymedon hydrochloride intake is prescribed per 0.25 g/thrice daily. Sanitation of wound surface is carried out in postoperative period due to putting aside the fragments developed and irrigating with 10%-xymedon hydrochloride aqueous solution. In peculiar case, at surgical treatment one should dissect surface fascia and interfacial fiber, and before developing the fragments one should direct fixing needles from each side along larger length and parallel to free edges. The method enables to provide the best aeration of wound surface, control the course of wound process and decrease the risk for development of hospital infection. EFFECT: higher efficiency of therapy. 1 cl, 1 dwg, 1 ex
BACKGROUND: To evaluate the efficacy of Cobas human papillomavirus (HPV) testing to predict cervical intraepithelial neoplasia of grade 2 or higher (CIN2+), Cobas HPV testing results were correlated with follow-up biopsy in patients from Cancer Prevention Center (CPC) and Gynecologic Oncology Clinic (GOC) of The University of Texas MD Anderson Cancer Center.
METHODS: Institutional data for patients who underwent Cobas HPV and Papanicolaou (Pap) cytology cotesting from 2019 to 2020 were retrospectively reviewed. Surgical follow-up results were compared with Cobas HPV testing results in two populations.
RESULTS: A total of 2226 patients, including 921 women (mean age, 55.2 years) seen at the CPC and 1305 women (mean age, 49.3 years) seen at the GOC, were included. Specimens from GOC patients had a significantly higher HPV positivity rate than did those from CPC patients (22.9% vs. 10.1%; p < .001). Cobas HPV testing was positive in all seven CPC patients with surgical follow-up results showing CIN2+. Among 36 GOC patients with CIN2+ lesions, five patients had HPV-/Pap+ testing results. Although only seven CPC patients had CIN2+, Cobas HPV testing showed 100% sensitivity for predicting CIN2+ in this group. Sensitivity for CIN2+ was 86.5% in the GOC group, whereas 13.9% of GOC patients with CIN2+ had negative HPV testing results.
CONCLUSIONS: Cobas HPV testing was highly efficacious for predicting CIN2+ lesions in the low-risk CPC population, which supports HPV primary screening for cervical cancer in low-risk populations. For high-risk patients, especially those with a history of CIN2+/cervical cancer, HPV/Pap cotesting may still be necessary to maintain a high clinical sensitivity for CIN2+.
BACKGROUND: Age-related macular degeneration (AMD) stands as the foremost cause of irreversible central vision impairment, marked by choroidal neovascularization (CNV). The prevailing clinical approach to AMD treatment relies on intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, this method is encumbered by diverse complications, prompting exploration of non-invasive alternatives such as ocular administration via eye drops for anti-VEGF therapy.
METHODS: Two complexes, 5-FITC-CPP-Ranibizumab (5-FCR) and 5-FITC-CPP-Conbercept (5-FCC), were synthesized by incorporating the anti-VEGF drugs Ranibizumab (RBZ) or Conbercept (CBC) with cell-penetrating peptide (CPP). Circular dichroism spectrum (CD) facilitated complexes characterization. Eye drops was utilized to address laser-induced CNV in mice. Fluorescein fundus angiography (FFA) observe the CNV lesion, while FITC-dextran and IB4 dual fluorescent staining, along with hematoxylin-eosin (HE) staining, assessed in lesion size. Tissue immunofluorescence examined CD31 and VEGF expression in choroidal/retinal pigment epithelial (RPE) tissues. Biocompatibility and biosafety of 5-FCR and 5-FCC was evaluated through histological examination of various organs or cell experiments.
RESULTS: Both 5-FCR and 5-FCC exhibited favorable biocompatibility and safety profiles. VEGF-induced migration of Human umbilical vein endothelial cells (HUVECs) significantly decreased post-5-FCR/5-FCC treatment. Additionally, both complexes suppressed VEGF-induced tube formation in HUVECs. FFA results revealed a significant improvement in retinal exudation in mice. Histological examination unveiled the lesion areas in the 5-FCR and 5-FCC groups showed a significant reduction compared to the control group. Similar outcomes were observed in histological sections of the RPE-choroid-sclera flat mounts.
CONCLUSION: In this study, utilizing the properties of CPP and two anti-VEGF drugs, we successfully synthesized two complexes, 5-FCR and 5-FCC, through a straightforward approach. Effectively delivering the anti-VEGF drugs to the target area in a non-invasive manner, suppressing the progression of laser-induced CNV. This offers a novel approach for the treatment of wet AMD.
In the prepn. of human kallikrein (I), (1) human cells capable of producing (I) are transplanted to a non-human, warmblooded animal and allowed to multiply. The cells are then allowed to liberate (I), or (2) human cells capable of producing (I) are placed in an appts. that supplies them with a nutritive medium from a non-human, warm-blooded animal and this is placed in or on the animal and allowed to multiply. The cells are then allowed to liberated (I). (I) is useful in the treatment of cerebral or cardia arteriosclerosis and hypertension. The process is cheaper to run on an industrial scale, and gives much greater yields, than conventional ways of preparing (I).
Chronic Obstructive Pulmonary Disease (COPD) frequently coincides with other comorbidities such as congestive heart failure, hypertension, coronary artery disease, or atrial fibrillation. The exhibition of overlapping sets of symptoms associated with these conditions prevents early identification of an acute exacerbation upon admission to a hospital. Early identification of the underlying cause of exacerbation allows timely prescription of an optimal treatment plan as well as allows avoiding unnecessary clinical tests and specialist consultations. The aim of this study was to develop a predictive model for early identification of COPD exacerbation by using the clinical notes generated within 24 hours of admission to the hospital. The study cohort included patients with a prior diagnosis of COPD. Four predictive models have been developed, among which the support vector machine showed the best performance based on the resulting 80% F1 score.
This is a 24 week double-blind study consisting of up to 11 office visits for people 18 years of age with aspirin exacerbated respiratory disease (AERD). 21 subjects will participate and will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair is a FDA approved medication for the treatment of moderate to severe allergic asthma. Injections will occur every 2-4 weeks, for 16 weeks. The dosage will be based upon IgE and body weight. Aspirin desensitization will occur 1-3 weeks later. One month after desensitization, the final visit will occur in the GCRC.

Properly selected patients with aspirin exacerbated respiratory disease (AERD) experience benefit in the course of their disease with aspirin desensitization treatment; however, AERD patients are at risk for potentially serious asthmatic reaction when undergoing aspirin desensitization. For this reason, this procedure is currently performed in a monitored setting. We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the aspirin desensitization will reduce severity of aspirin-induced respiratory reaction, and that ultimately, use of Xolair will permit this procedure to be performed safely in outpatient settings. This protocol also entails obtaining blood and urine samples to assess the influence of Xolair, compared with placebo. As aspirin induced reaction occurs via heightened release of leukotrienes combined with greater end organ responsiveness to these mediators, we also will be quantifying the impact of prior administration of Xolair, compared with placebo, on the elevation of urinary LTE4 in association with aspirin challenge and with aspirin provoked reaction.
The present invention relates to plaster for treating hyperosteogeny, which is prepared from Yunnan wintergreen stem and leaf, mole cricket and game fowl. The Yunnan wintergreen stem and leaf is dried and pulverized after extraction; the mole cricket and the game fowl are respectively pulverized for standby; sesame oil, wood grease and rosin are mixed and heated; the mole cricket and the game fowl are added and are stirred; the temperature of the mole cricket and the game fowl is reduced; Yunnan wintergreen stem and leaf powder is added; thus, the plaster is formed after stirring. The present invention has the advantages of no treatment pain, convenient medicine taking, good curative effect, etc. The Yunnan wintergreen stem and leaf has the functions of circulation stimulation, stasis elimination, rheumatism elimination, detoxification, absorption promotion with volatile oil. The mole cricket and the game fowl can help the Yunnan wintergreen stem and leaf detumescence and pain alleviation. The Yunnan wintergreen stem and leaf, the mole cricket and the game fowl are taken together so as to display the efficiency of circulation stimulation, stasis elimination, hardness softening, channel freeing, rheumatism removal, detumescence and pain alleviation.
BACKGROUND: Pediatric cancer survivors are at increased risk of muscle weakness and low areal bone mineral density (aBMD). However, the prevalence of muscle strength deficits is not well documented, and the associations of muscle strength with aBMD are unknown in this population. Therefore, this study aimed to investigate the prevalence of upper- and lower-body muscle strength deficits and to examine the associations of upper- and lower-body muscle strength with age-, sex, and race-specific aBMD Z-scores at the total body, total hip, femoral neck, and lumbar spine.
METHODS: This cross-sectional study included 116 pediatric cancer survivors (12.1 ± 3.3 years old, mean ± SD; 42.2% female). Upper- and lower-body muscle strength were assessed by handgrip and standing long jump test, respectively. Dual‑energy X‑ray absorptiometry was used to measure aBMD (g/cm2). Associations between muscle strength and aBMD were evaluated in multivariable linear regression models. Logistic regression was used to evaluate the contribution of muscle strength (1-decile lower) to the odds of having low aBMD (Z-score ≤ 1.0). All analyses were adjusted for time from treatment completion, radiotherapy exposure, and body mass index.
RESULTS: More than one-half of survivors were within the 2 lowest deciles for upper- (56.9%) and lower- body muscle strength (60.0%) in comparison to age- and sex-specific reference values. Muscle strength deficits were associated with lower aBMD Z-scores at all sites (B = 0.133-0.258, p = 0.001-0.032). Each 1-decile lower in upper-body muscle strength was associated with 30%-95% higher odds of having low aBMD Z-scores at all sites. Each 1-decile lower in lower-body muscle strength was associated with 35%-70% higher odds of having low aBMD Z-scores at total body, total hip, and femoral neck.
CONCLUSION: Muscle strength deficits are prevalent in young pediatric cancer survivors, and such deficits are associated with lower aBMD Z-scores at all sites. These results suggest that interventions designed to improve muscle strength in this vulnerable population may have the added benefit of improving aBMD.
547,910. Hormones. SOCIETY OF CHEMICAL INDUSTRY IN BASLE. Jan. 17, 1941, No. 665. Convention date, Jan. 18, 1940. [Class 81 (i)] Gonadotropic hormones of the pituitary gland are concentrated by treating a solution of the hormone with a strong acid albumen-precipitant (other than a phenolic polynitro compound), e.g. sulphosalicylic or trichloracetic acid, separating the precipitate, removing excess of acid from the solution and precipitating the hormone by the addition of a phenolic polynitro compound such as picric or picrolonic acid and separating the hormone from the precipitant in known manner.
A reduction in the side effects of treating with an agent having combined 5HT 2 /5HT 3  and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. A combined dosage form comprising an agent having 5HT 2 /5HT 3  and alpha-2 antagonistic activity and an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT 2 /5HT 3  and alpha-2 antagonistic activity and a delayed release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine H1 agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT 2 /5HT 3  and alpha-2 antagonistic activity and an immediate release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine H1 agonist activity. Methods of treatment comprising administration of such a dosage form after waking are also provided. Also provided are kits for administration of the first therapeutic agent having 5HT 2 /5HT 3  and alpha-2 antagonistic activity and the second therapeutic agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. The kits include instructions for the administration of the first therapeutic agent having 5HT 2 /5HT 3  and alpha-2 antagonistic activity prior to bed and the second agent having selective norepinephrine reuptake inhibitory activity or histamine H1 agonist activity after waking. In some embodiments, the invention provides synergistic combinations of 5HT 2 /5HT 3  antagonist/alpha-2 antagonist and selective norepinephrine reuptake inhibitor or histamine H1 agonist.